External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

Teva Pharmaceutical Sp Adr / Equity Bottom-Up

<ul><li>Teva Pharmaceuticals and Viatris Inc are leading global generic pharmaceutical manufacturers with diverse drug portfolios.</li><li>Both companies are currently undervalued and are anticipated to see substantial shareholder returns in 2024.</li><li>Despite challenges in the US generic drug industry, Teva and Viatris are poised for significant upside potential in the near future.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Teva Pharmaceuticals and Viatris Inc are leading global generic pharmaceutical manufacturers with diverse drug portfolios.Both companies are currently undervalued and are anticipated to see substantial shareholder returns in 2024.Despite challenges in the US generic drug industry, Teva and Viatris are poised for significant upside potential in the near future.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Teva Pharmaceuticals (TEVA) - Tuesday, Jan 16, 2024

Israel

Teva Pharmaceutical Industries Ltd., is a global pharmaceutical company. The Company develops, manufactures, and markets generic and branded human pharmaceuticals as well as active pharmaceutical ingredients.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00